This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00777/identifier/kegg-compound/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00777/identifier/pubchem-compound/
n17http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00777/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00777/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00777/identifier/drugbank/
n21http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00777/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00777/identifier/chebi/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00777/identifier/wikipedia/
n8http://linked.opendata.cz/ontology/sukl/drug/
n9http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00777/identifier/pharmgkb/

Statements

Subject Item
n2:DB00777
rdf:type
n3:Drug
n3:description
Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors.
n3:group
approved
n3:indication
Propiomazine is largely used for its antihistamininc sleep inducing effects in treating insomnia.
n3:manufacturer
n17:271B5EBB-363D-11E5-9242-09173F13E4C5 n17:271B5EBA-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00777 n21:DB00777
dcterms:title
Propiomazine
adms:identifier
n6:46506205 n7:PA164778685 n10:Propiomazine n14:4771 n15:DB00777 n16:8491 n18:4940 n19:C07405 n20:D02361
n3:mechanismOfAction
Propiomazine is an antagonist at types 1, 2, and 4 dopamine receptors, serotonin (5-HT) receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Its main use as a sedative is due to its antihistamine effect.
n3:synonym
Propiomazine 2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine Propiomazin Propiomazina Propiomazinum 3-Propionyl-10-dimethylaminoisopropylphenothiazine 10-(2-Dimethylaminopropyl)-2-propionylphenothiazine
n3:toxicity
Rare, serious side effects include convulsions (seizures); difficult or unusually fast breathing; fast or irregular heartbeat or pulse; fever (high); high or low blood pressure; loss of bladder control; muscle stiffness (severe); unusual increase in sweating; unusually pale skin; and unusual tiredness or weakness.
n3:proteinBinding
81%
n3:IUPAC-Name
n4:271B5EC0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5EC6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5EC5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5EC2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5EC3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5EC4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5ED6-363D-11E5-9242-09173F13E4C5 n4:271B5EBE-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5EBC-363D-11E5-9242-09173F13E4C5 n4:271B5EBF-363D-11E5-9242-09173F13E4C5 n4:271B5ED7-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5EBD-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:N05CM06
n3:H-Bond-Acceptor-Count
n4:271B5ECC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5ECD-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5EC7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5EC8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5ECA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5EC9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5ECB-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
362-29-8
n3:category
n3:Bioavailability
n4:271B5ED2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5ED4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5ED5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5ED1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5ED0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5ED3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5EC1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5ECE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5ECF-363D-11E5-9242-09173F13E4C5